1
|
Abstract
Cholix (Chx) is secreted by non-pandemic strains of Vibrio cholerae in the intestinal lumen. For this exotoxin to induce cell death in non-polarized cells in the intestinal lamina propria, it must traverse the epithelium in the fully intact form. We identified host cell elements in polarized enterocytes associated with Chx endocytosis and apical to basal (A→B) vesicular transcytosis. This pathway overcomes endogenous mechanisms of apical vesicle recycling and lysosomal targeting by interacting with several host cell proteins that include the 75 kDa glucose-regulated protein (GRP75). Apical endocytosis of Chx appears to involve the single membrane spanning protein TMEM132A, and interaction with furin before it engages GRP75 in apical vesicular structures. Sorting within these apical vesicles results in Chx being trafficked to the basal region of cells in association with the Lectin, Mannose Binding 1 protein LMAN1. In this location, Chx interacts with the basement membrane-specific heparan sulfate proteoglycan perlecan in recycling endosomes prior to its release from this basal vesicular compartment to enter the underlying lamina propria. While the furin and LMAN1 elements of this Chx transcytosis pathway undergo cellular redistribution that are reflective of the polarity shifts noted for coatamer complexes COPI and COPII, GRP75 and perlecan fail to show these dramatic rearrangements. Together, these data define essential steps in the A→B transcytosis pathway accessed by Chx to reach the intestinal lamina propria where it can engage and intoxicate certain non-polarized cells.
Collapse
Affiliation(s)
- Keyi Liu
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Tom Hunter
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Alistair Taverner
- Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
| | - Kevin Yin
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Julia MacKay
- Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
| | - Kate Colebrook
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Morgan Correia
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Amandine Rapp
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Randall J. Mrsny
- Applied Molecular Transport, South San Francisco, CA, USA,Department of Pharmacy and Pharmacology, University of Bath, Bath, UK,CONTACT Randall J. Mrsny Applied Molecular Transport, 450 East Jamie Court, South San Francisco, CA94080USA
| |
Collapse
|
2
|
Fay NC, Muthusamy BP, Nyugen LP, Desai RC, Taverner A, MacKay J, Seung M, Hunter T, Liu K, Chandalia A, Coyle MP, Kim HL, Postlethwaite S, Mangat K, Song L, Seto E, Alam A, Olson CV, Feng W, Saberi M, Mahmood TA, Mrsny RJ. A Novel Fusion of IL-10 Engineered to Traffic across Intestinal Epithelium to Treat Colitis. J Immunol 2020; 205:3191-3204. [PMID: 33148717 DOI: 10.4049/jimmunol.2000848] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 10/03/2020] [Indexed: 01/08/2023]
Abstract
IL-10 is a potent anti-inflammatory cytokine capable of suppressing a number of proinflammatory signals associated with intestinal inflammatory diseases, such as ulcerative colitis and Crohn's disease. Clinical use of human IL-10 (hIL-10) has been limited by anemia and thrombocytopenia following systemic injection, side effects that might be eliminated by a gut-restricted distribution. We have identified a transcytosis pathway used by cholix, an exotoxin secreted by nonpandemic forms of the intestinal pathogen Vibrio cholerae A nontoxic fragment of the first 386 aa of cholix was genetically fused to hIL-10 to produce recombinant AMT-101. In vitro and in vivo characterization of AMT-101 showed it to efficiently cross healthy human intestinal epithelium (SMI-100) by a vesicular transcytosis process, activate hIL-10 receptors in an engineered U2OS osteosarcoma cell line, and increase cellular phospho-STAT3 levels in J774.2 mouse macrophage cells. AMT-101 was taken up by inflamed intestinal mucosa and activated pSTAT3 in the lamina propria with limited systemic distribution. AMT-101 administered to healthy mice by oral gavage or to cynomolgus monkeys (nonhuman primates) by colonic spray increased circulating levels of IL-1R antagonist (IL-1Ra). Oral gavage of AMT-101 in two mouse models of induced colitis prevented associated pathological events and plasma cytokine changes. Overall, these studies suggest that AMT-101 can efficiently overcome the epithelial barrier to focus biologically active IL-10 to the intestinal lamina propria.
Collapse
Affiliation(s)
- Nicole C Fay
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | | | - Linh P Nyugen
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Radhika C Desai
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Alistair Taverner
- Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY Bath, United Kingdom
| | - Julia MacKay
- Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY Bath, United Kingdom
| | - Minji Seung
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Tom Hunter
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Keyi Liu
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | | | - Michael P Coyle
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Hyojin L Kim
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | | | | | - Lisa Song
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Elbert Seto
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Aatif Alam
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Charles V Olson
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Weijun Feng
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Maziyar Saberi
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Tahir A Mahmood
- Applied Molecular Transport, South San Francisco, CA 94080; and
| | - Randall J Mrsny
- Applied Molecular Transport, South San Francisco, CA 94080; and .,Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY Bath, United Kingdom
| |
Collapse
|
3
|
Taverner A, MacKay J, Laurent F, Hunter T, Liu K, Mangat K, Song L, Seto E, Postlethwaite S, Alam A, Chandalia A, Seung M, Saberi M, Feng W, Mrsny RJ. Cholix protein domain I functions as a carrier element for efficient apical to basal epithelial transcytosis. Tissue Barriers 2020; 8:1710429. [PMID: 31928299 PMCID: PMC7063863 DOI: 10.1080/21688370.2019.1710429] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Cholix (Chx) is expressed by the intestinal pathogen Vibrio cholerae as a single chain of 634 amino acids (~70.7 kDa protein) that folds into three distinct domains, with elements of the second and third domains being involved in accessing the cytoplasm of nonpolarized cells and inciting cell death via ADP-ribosylation of elongation factor 2, respectively. In order to reach nonpolarized cells within the intestinal lamina propria, however, Chx must cross the polarized epithelial barrier in an intact form. Here, we provide in vitro and in vivo demonstrations that a nontoxic Chx transports across intestinal epithelium via a vesicular trafficking pathway that rapidly achieves vesicular apical to basal (A→B) transcytosis and avoids routing to lysosomes. Specifically, Chx traffics in apical endocytic Rab7+ vesicles and in basal exocytic Rab11+ vesicles with a transition between these domains occurring in the ER-Golgi intermediate compartment (ERGIC) through interactions with the lectin mannose-binding protein 1 (LMAN1) protein that undergoes an intracellular re-distribution that coincides with the re-organization of COPI+ and COPII+ vesicular structures. Truncation studies demonstrated that domain I of Chx alone was sufficient to efficiently complete A→B transcytosis and capable of ferrying genetically conjoined human growth hormone (hGH). These studies provide evidence for a pathophysiological strategy where native Chx exotoxin secreted in the intestinal lumen by nonpandemic V. cholerae can reach nonpolarized cells within the lamina propria in an intact form by using a nondestructive pathway to cross in the intestinal epithelial that appears useful for oral delivery of biopharmaceuticals.One-Sentence Summary: Elements within the first domain of the Cholix exotoxin protein are essential and sufficient for the apical to basal transcytosis of this Vibrio cholerae-derived virulence factor across polarized intestinal epithelial cells.
Collapse
Affiliation(s)
- Alistair Taverner
- Department of Pharmacy and Pharmacology, University of Bath, Bath, England
| | - Julia MacKay
- Department of Pharmacy and Pharmacology, University of Bath, Bath, England
| | - Floriane Laurent
- Department of Pharmacy and Pharmacology, University of Bath, Bath, England
| | - Tom Hunter
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Keyi Liu
- Applied Molecular Transport, South San Francisco, CA, USA
| | | | - Lisa Song
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Elbert Seto
- Applied Molecular Transport, South San Francisco, CA, USA
| | | | - Aatif Alam
- Applied Molecular Transport, South San Francisco, CA, USA
| | | | - Minji Seung
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Mazi Saberi
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Weijun Feng
- Applied Molecular Transport, South San Francisco, CA, USA
| | - Randall J Mrsny
- Department of Pharmacy and Pharmacology, University of Bath, Bath, England.,Applied Molecular Transport, South San Francisco, CA, USA
| |
Collapse
|
4
|
Almansour K, Taverner A, Eggleston IM, Mrsny RJ. Mechanistic studies of a cell-permeant peptide designed to enhance myosin light chain phosphorylation in polarized intestinal epithelia. J Control Release 2018; 279:208-219. [PMID: 29614254 DOI: 10.1016/j.jconrel.2018.03.033] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Revised: 03/26/2018] [Accepted: 03/27/2018] [Indexed: 12/15/2022]
Abstract
Tight junction (TJ) structures restrict the movement of solutes between adjacent epithelial cells to maintain homeostatic conditions. A peptide, termed PIP 640, with the capacity to regulate the transient opening of intestinal TJ structures through an endogenous mechanism involving the induction of myosin light chain (MLC) phosphorylation at serine 19 (MLC-pS19) has provided a promising new method to enhance the in vivo oral bioavailability of peptide therapeutics. PIP 640 is a decapeptide composed of all D-amino acids (rrdykvevrr-NH2) that contains a central sequence designed to emulates a specific domain of C-kinase potentiated protein phosphatase-1 inhibitor-17 kDa (CPI-17) surrounded by positively-charged amino acids that provide a cell penetrating peptide (CPP)-like character. Here, we examine compositional requirements of PIP 640 with regard to its actions on MLC phosphorylation, its intracellular localization to TJ structures, and its interactions with MLC phosphatase (MLCP) elements that correlate with enhanced solute uptake. These studies showed that a glutamic acid and tyrosine within this peptide are critical for PIP 640 to retain its ability to increase MLC-pS19 levels and enhance the permeability of macromolecular solutes of the size range of therapeutic peptides without detectable cytotoxicity. On the other hand, exchange of the aspartic acid for alanine and then arginine resulted in an increasingly greater bias toward protein phosphatase-1 (PP1) relative to MLCP inhibition, an outcome that resulted in increased paracellular permeability for solutes in the size range of therapeutic peptides, but with a significant increase in cytotoxicity. Together, these data further our understanding of the composition requirements of PIP 640 with respect to the desired goal of transiently altering the intestinal epithelial cell paracellular barrier properties through an endogenous mechanism, providing a novel approach to enhance the oral bioavailability of poorly absorbed therapeutic agents of < ~ 5 kDa.
Collapse
Affiliation(s)
- Khaled Almansour
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Alistair Taverner
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Ian M Eggleston
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Randall J Mrsny
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
| |
Collapse
|
5
|
Taverner A, Dondi R, Almansour K, Laurent F, Owens SE, Eggleston IM, Fotaki N, Mrsny RJ. Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J Control Release 2015; 210:189-97. [PMID: 25980620 PMCID: PMC4504001 DOI: 10.1016/j.jconrel.2015.05.270] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 05/09/2015] [Accepted: 05/11/2015] [Indexed: 01/03/2023]
Abstract
The intestinal epithelium functions to effectively restrict the causal uptake of luminal contents but has been demonstrated to transiently increase paracellular permeability properties to provide an additional entry route for dietary macromolecules. We have examined a method to emulate this endogenous mechanism as a means of enhancing the oral uptake of insulin. Two sets of stable Permeant Inhibitor of Phosphatase (PIP) peptides were rationally designed to stimulate phosphorylation of intracellular epithelial myosin light chain (MLC) and screened using Caco-2 monolayers in vitro. Apical application of PIP peptide 640, designed to disrupt protein–protein interactions between protein phosphatase 1 (PP1) and its regulator CPI-17, resulted in a reversible and non-toxic transient reduction in Caco-2 monolayer trans-epithelial electric resistance (TEER) and opening of the paracellular route to 4 kDa fluorescent dextran but not 70 kDa dextran in vitro. Apical application of PIP peptide 250, designed to impede MYPT1-mediated regulation of PP1, also decreased TEER in a reversible and non-toxic manner but transiently opened the paracellular route to both 4 and 70 kDa fluorescent dextrans. Direct injection of PIP peptides 640 or 250 with human insulin into the lumen of rat jejunum caused a decrease in blood glucose levels that was PIP peptide and insulin dose-dependent and correlated with increased pMLC levels. Systemic levels of insulin suggested approximately 3–4% of the dose injected into the intestinal lumen was absorbed, relative to a subcutaneous injection. Measurement of insulin levels in the portal vein showed a time window of absorption that was consistent with systemic concentration-time profiles and approximately 50% first-pass clearance by the liver. Monitoring the uptake of a fluorescent form of insulin suggested its uptake occurred via the paracellular route. Together, these studies add validation to the presence of an endogenous mechanism used by the intestinal epithelium to dynamically regulate its paracellular permeability properties and better define the potential to enhance the oral delivery of biopharmaceuticals via a transient regulation of an endogenous mechanism controlling the intestinal paracellular barrier.
Collapse
Affiliation(s)
- Alistair Taverner
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Ruggero Dondi
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Khaled Almansour
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Floriane Laurent
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Siân-Eleri Owens
- Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK
| | - Ian M Eggleston
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Nikoletta Fotaki
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | - Randall J Mrsny
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
| |
Collapse
|
6
|
Cordery SF, Taverner A, Ridzwan IE, Guy RH, Delgado-Charro MB, Husbands SM, Bailey CP. A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addict Biol 2014; 19:575-86. [PMID: 23240906 DOI: 10.1111/adb.12020] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Concurrent use of cocaine and heroin is a major public health issue with no effective relapse prevention treatment currently available. To this purpose, a combination of buprenorphine and naltrexone, a mixed very-low efficacy mu-opioid receptor agonist/kappa-opioid receptor antagonist/nociceptin receptor agonist, was investigated. The tail-withdrawal and the conditioned place preference (CPP) assays in adult Sprague Dawley rats were used to show that naltrexone dose-dependently blocked the mu-opioid receptor agonism of buprenorphine. Furthermore, in the CPP assay, a combination of 0.3 mg/kg buprenorphine and 3.0 mg/kg naltrexone was aversive. A combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone was neither rewarding nor aversive, but still possessed mu-opioid receptor antagonist properties. In the CPP extinction and reinstatement method, a combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone completely blocked drug-primed reinstatement in cocaine-conditioned rats (conditioned with 3 mg/kg cocaine, drug prime was 3 mg/kg cocaine) and attenuated drug-primed reinstatement in morphine-conditioned rats (conditioned with 5 mg/kg morphine, drug prime was 1.25 mg/kg morphine). These data add to the growing evidence that a buprenorphine/naltrexone combination may be protective against relapse in a polydrug abuse situation.
Collapse
Affiliation(s)
| | | | - Irna E. Ridzwan
- Department of Pharmacy and Pharmacology; University of Bath; UK
| | - Richard H. Guy
- Department of Pharmacy and Pharmacology; University of Bath; UK
| | | | | | | |
Collapse
|
7
|
Taverner A, Cordery S, Husbands SM, Guy RH, Delgado-Charro BM, Bailey CP. Transdermal delivery of a buprenorphine/naltrexone combination for the treatment of polydrug abuse. Pharmacol Rep 2011. [DOI: 10.1016/s1734-1140(11)70484-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|